KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Change in Account Payables (2017 - 2025)

Twist Bioscience (TWST) has disclosed Change in Account Payables for 7 consecutive years, with $1.9 million as the latest value for Q3 2023.

  • On a quarterly basis, Change in Account Payables fell 72.2% to $1.9 million in Q3 2023 year-over-year; TTM through Sep 2023 was -$2.5 million, a 133.97% decrease, with the full-year FY2025 number at $9.3 million, up 179.05% from a year prior.
  • Change in Account Payables was $1.9 million for Q3 2023 at Twist Bioscience, up from -$220000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $6.9 million in Q3 2022 to a low of -$7.5 million in Q1 2023.
  • A 5-year average of $626526.3 and a median of $339000.0 in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: skyrocketed 65740.0% in 2022, then plummeted 889.83% in 2023.
  • Twist Bioscience's Change in Account Payables stood at -$556000.0 in 2019, then soared by 722.12% to $3.5 million in 2020, then tumbled by 100.14% to -$5000.0 in 2021, then surged by 65740.0% to $3.3 million in 2022, then plummeted by 41.41% to $1.9 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Change in Account Payables are $1.9 million (Q3 2023), -$220000.0 (Q2 2023), and -$7.5 million (Q1 2023).